Cannabis Player Clever Leaves Could Have Almost 390% Upside Due To Overseas Exposure, This Analyst Says
Cantor Fitzgerald has initiated coverage on Clever Leaves Holdings Inc (NASDAQ: CLVR) with an Overweight rating and a price target of $4.50.
The stock offers better relative "pure-play" exposure to growth in overseas medical cannabis markets and eventually to recreational legalization in those markets, Cantor writes.
According to the analyst Clever Leaves, a large-scale, low-cost producer of pharmaceutical-grade cannabis, could be among the world's top five cannabinoid exporters by the end of 2023.
Also See: Clever Leaves To Ship First Export Of Cannabis To Israeli Partner InterCure.
G-7 producers dominate end markets like Germany, but CLVR management expects to gain market share as more markets open to Colombian and Portuguese THC flowers.
The company also benefits from several new distribution agreements, and its growth costs are sometimes one-tenth that of Canadian growers.
With only $2 million in cannabinoid exports, there is a "show me" story for now. Cantor models CLVR cannabinoid sales of $27 million by 2023.
The company has $27 million left in an equity facility that will be tapped in the months ahead. News flow about rec legalization in markets like Germany and Colombia may provide windows of opportunity for capital raises.
Price Action: CLVR shares are up 3.26% at $0.95 during the market session on the last check Monday.
Latest Ratings for CLVR
Date | Firm | Action | From | To |
|---|---|---|---|---|
Dec 2021 | Canaccord Genuity | Maintains | Buy | |
Nov 2021 | Canaccord Genuity | Maintains | Buy | |
Jul 2021 | Canaccord Genuity | Initiates Coverage On | Buy |
View More Analyst Ratings for CLVR
View the Latest Analyst Ratings
See more from Benzinga
Concert Pharma Aces Second Trial For Patchy Hair Loss Hopeful
After FDA Hold, Nuvation Bio Stops NUV-422 Cancer Development Program
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
